To What Extent Can Biosimilars Compete with Brand Name Biologics? A EU-5 Granulocyte-Colony Stimulating Factors Markets Analysis

I. Fusier, A.L. Cordonnier, P. Paubel, François Bocquet and Claude Le Pen
Additional contact information
I. Fusier: Hôpital Necker - Enfants Malades [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
A.L. Cordonnier: Hôpital Necker - Enfants Malades [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
P. Paubel: IDS - U1145 - Institut Droit et Santé - UPD5 - Université Paris Descartes - Paris 5 - INSERM - Institut National de la Santé et de la Recherche Médicale
François Bocquet: IDS - U1145 - Institut Droit et Santé - UPD5 - Université Paris Descartes - Paris 5 - INSERM - Institut National de la Santé et de la Recherche Médicale
Claude Le Pen: LEDa - Laboratoire d'Economie de Dauphine - IRD - Institut de Recherche pour le Développement - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres - CNRS - Centre National de la Recherche Scientifique

Post-Print from HAL

Keywords: Brand Name Biologics; Markets Analysis (search for similar items in EconPapers)
Date: 2013
References: Add references at CitEc
Citations:

Published in Value in Health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2013, 16 (7), ⟨10.1016/j.jval.2013.08.763⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01507506

DOI: 10.1016/j.jval.2013.08.763

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().